Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
| Autor: | Fanny De La Fuente, Rakiba Belkhir, Julien Henry, Chi Duc Nguyen, Thao Pham, Vincent Germain, Pierre Edouard Gavand, Céline Labadie, Claire Briere, Ambre Lauret, Thierry Cardon, Gael Mouterde, Isabelle Bonnet, Léa Rouxel, Marie-Elise Truchetet, Thierry Schaeverbeke, Christophe Richez, Marie Kostine |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
Immunology Arthritis Rheumatoid Interleukin 1 Receptor Antagonist Protein Methotrexate Rheumatology Antirheumatic Agents Immunology and Allergy Humans Janus Kinase Inhibitors Female Tumor Necrosis Factor Inhibitors Ustekinumab Drug Therapy Combination Immune Checkpoint Inhibitors Glucocorticoids Aged Retrospective Studies |
| Zdroj: | RMD open. 8(2) |
| ISSN: | 2056-5933 |
| Popis: | ObjectiveThere is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting.MethodsUsing the Club Rhumatismes and Inflammation French network, we conducted a multicentre, retrospective, observational study of patients with cancer diagnosed with inflammatory arthritis under ICI(s) and treated with bDMARD or JAKi. Clinical data were collected using a standardised case report form.ResultsTwenty patients (60% men, median age 69.5 years) were included, with rheumatoid arthritis (RA)-like (n=16), polymyalgia rheumatica-like (n=2) or psoriatic arthritis-like (n=2) clinical presentation. Two patients had pre-existing RA. 90% were treated with glucocorticoids as first-line therapy and 60% received methotrexate prior to bDMARD or JAKi. Anti-interleukin-6 receptor (IL-6R) therapy was used in 13/20 patients (65%), leading to clinical improvement in 11/13 patients (85%), but one patient experienced intestinal perforation and cancer progression was noticed in 6/13 patients (46%). Tumour necrosis factor inhibitors were used in 5/20 patients (25%), with improvement in 4/5 patients (80%) and cancer progression was observed in 3/5 patients (60%). Two infections (diverticulitis and pneumonitis) were reported. Anakinra, baricitinib and ustekinumab were each used in one patient. Median duration of the bDMARD or JAKi was 17 weeks.ConclusionAnti-IL-6R therapy is currently the most common strategy in patients with ICI-induced inflammatory arthritis and insufficient response to glucocorticoids and methotrexate, leading to improvement in >80%. Overall, cancer progression occurred in about half of patients and whether the bDMARD/JAKi impacted the tumour response remains to be determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|